232 related articles for article (PubMed ID: 36357283)
21. Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification.
Lee WH; Tsai MT; Tsai CH; Tien FM; Lo MY; Tseng MH; Kuo YY; Liu MC; Yang YT; Chen JC; Tang JL; Sun HI; Chuang YK; Lin LI; Chou WC; Lin CC; Hou HA; Tien HF
Blood Cancer J; 2023 Aug; 13(1):120. PubMed ID: 37558665
[TBL] [Abstract][Full Text] [Related]
22. Lower risk but high risk.
DeZern AE
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):428-434. PubMed ID: 34889376
[TBL] [Abstract][Full Text] [Related]
23. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS).
Germing U; Hildebrandt B; Pfeilstöcker M; Nösslinger T; Valent P; Fonatsch C; Lübbert M; Haase D; Steidl C; Krieger O; Stauder R; Giagounidis AA; Strupp C; Kündgen A; Mueller T; Haas R; Gattermann N; Aul C
Leukemia; 2005 Dec; 19(12):2223-31. PubMed ID: 16193087
[TBL] [Abstract][Full Text] [Related]
24. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
[TBL] [Abstract][Full Text] [Related]
25. When to use which molecular prognostic scoring system in the management of patients with MDS?
Kewan T; Bewersdorf JP; Gurnari C; Xie Z; Stahl M; Zeidan AM
Best Pract Res Clin Haematol; 2023 Dec; 36(4):101517. PubMed ID: 38092484
[TBL] [Abstract][Full Text] [Related]
26. The evolving role of genomic testing in assessing prognosis of patients with myelodysplastic syndromes.
Steensma DP
Best Pract Res Clin Haematol; 2017 Dec; 30(4):295-300. PubMed ID: 29156198
[TBL] [Abstract][Full Text] [Related]
27. Molecular landscape of myelodysplastic neoplasms in disease classification and prognostication.
Maggioni G; Della Porta MG
Curr Opin Hematol; 2023 Mar; 30(2):30-37. PubMed ID: 36728601
[TBL] [Abstract][Full Text] [Related]
28. Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register.
Moreno Berggren D; Folkvaljon Y; Engvall M; Sundberg J; Lambe M; Antunovic P; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellström-Lindberg E; Jädersten M; Ejerblad E
Br J Haematol; 2018 Jun; 181(5):614-627. PubMed ID: 29707769
[TBL] [Abstract][Full Text] [Related]
29. Molecular Drivers of Myelodysplastic Neoplasms (MDS)-Classification and Prognostic Relevance.
Hoff FW; Madanat YF
Cells; 2023 Feb; 12(4):. PubMed ID: 36831294
[TBL] [Abstract][Full Text] [Related]
30. The search for better prognostic models in myelodysplastic syndromes.
Santos FP; Kantarjian H; Garcia-Manero G; Ravandi F
Curr Hematol Malig Rep; 2011 Mar; 6(1):13-21. PubMed ID: 21136214
[TBL] [Abstract][Full Text] [Related]
31. Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome.
Hou HA; Tsai CH; Lin CC; Chou WC; Kuo YY; Liu CY; Tseng MH; Peng YL; Liu MC; Liu CW; Liao XW; Lin LI; Yao M; Tang JL; Tien HF
Blood Cancer J; 2018 Apr; 8(4):39. PubMed ID: 29618722
[TBL] [Abstract][Full Text] [Related]
32. Does mutational burden add to other prognostic factors in MDS?
Nazha A
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101098. PubMed ID: 31779975
[TBL] [Abstract][Full Text] [Related]
33. How low risk are low risk myelodysplastic syndromes?
DeZern AE; Dalton WB
Expert Rev Hematol; 2022 Jan; 15(1):15-24. PubMed ID: 35041576
[TBL] [Abstract][Full Text] [Related]
34. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
Garcia-Manero G
Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
[TBL] [Abstract][Full Text] [Related]
35. The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes.
DeZern AE; Greenberg PL
Blood; 2023 Dec; 142(26):2258-2267. PubMed ID: 37562001
[TBL] [Abstract][Full Text] [Related]
36. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol; 2014 Jan; 89(1):97-108. PubMed ID: 24464505
[TBL] [Abstract][Full Text] [Related]
37. A novel scoring system integrating molecular abnormalities with IPSS-R can improve the risk stratification in patients with MDS.
Gu S; Xia J; Tian Y; Zi J; Ge Z
BMC Cancer; 2021 Feb; 21(1):134. PubMed ID: 33549060
[TBL] [Abstract][Full Text] [Related]
38. Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS.
Nazha A; Bejar R
Curr Hematol Malig Rep; 2017 Oct; 12(5):461-467. PubMed ID: 28844082
[TBL] [Abstract][Full Text] [Related]
39. Incorporating mutations and bone marrow fibrosis into the revised international prognostic scoring system in myelodysplastic syndromes.
Zhao Y; Guo J; Zhao S; Wang R; Wu D; Chang C
Leuk Lymphoma; 2024 Jan; 65(1):100-108. PubMed ID: 37865969
[TBL] [Abstract][Full Text] [Related]
40. Configuration of the TP53 gene as an independent prognostic parameter of myelodysplastic syndrome.
Horiike S; Kita-Sasai Y; Nakao M; Taniwaki M
Leuk Lymphoma; 2003 Jun; 44(6):915-22. PubMed ID: 12854888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
